Quantitative and phenotypic transformation of CD16+IFNα/βR1-CD119+, CD16+IFNα/βR1+CD119- and CD16+IFNα/βR1+CD119+ neutrophil granulocytes subsets in patients with post-COVID syndrome

Cover Page

Cite item

Full Text

Abstract

In patients who underwent COVID-19, various manifestations of post-COVID syndrome (PCS) are noted, causing the development of disorders accompanying severe viral infections, complicated by chronic fatigue syndrome (CFS) and severe cognitive disorders (CD). Studying the molecular mechanisms of these disorders in the system of neutrophilic granulocytes (NG) in patients with PCS associated with IFN production, receptor function of NG, in particular, their subsets expressing IFNα/βR, IFNγR(CD119), is relevant for the search for therapeutic strategies, restoration and enhancement of the innate immune response after COVID-19.

Our objective was to clarify the quantitative and phenotypic characteristics of certain subsets of neutrophil granulocytes, i.e., CD16+IFNα/βR1-CD119+, CD16+IFNα/βR1+CD119-, CD16+IFNα/βR1+CD119+, in peripheral blood of patients with post-COVID syndrome.

We have examined 39 patients (24-60 years old) with PCS 3 months after COVID-19 (study group 1, SG1). The comparison group (CG) included 30 volunteers examined over the pre-COVID period. Detection of herpesvirus infections (HSV1, EBV, HHV6, CMV) was carried out in scrapings from the tonsils and the posterior wall of the pharynx. To determine the severity of the clinical PCS symptoms, a questionnaire was used to assess its severity using a point scale. The content and phenotype of NG subsets CD16+IFNα/βR1-CD119+, CD16+IFNα/βR1+CD119-, CD16+IFNα/βR1+CD119+ were assessed by means of FC 500 (Beckman Coulter, USA).

In all patients of SG1, clinical manifestations of CFS and CD were revealed, at the average severity rates of 16.0 points (14.75-20.25). When detecting herpesvirus infections, 37.2% had only HSV1 infection; 62.8% of patients showed mixed infection (HSV1, EBV, HHV6), which exhibited more pronounced clinical symptoms. We have noted absence of CD16+IFNα/βR1+CD119+NG subset and phenotype transformation of CD16+IFNα/βR1-CD119+NG, CD16+IFNα/βR1+CD119-NG subsets. Increased density expression of CD16, IFNα/βR1, CD119 receptors was also found (p1-3 < 0.05) thus suggesting ability to accept the interferon signaling and response.

Reduced infectious burden in the post-COVID period and adequate functioning of the immune system, including the neuroimmunoendocrine regulation mechanisms, should contribute to the functional recovery of various organs, systems, thus neutralizing the PCS manifestations. Therefore, usage of recIFNα2b in combination with highly active antioxidants may contribute to development of protective immunity, prevention of acute respiratory viral infections, exacerbation of chronic infections, and restoration of the NG phenotypes followed by restoration of anti-infectious immune balance.

About the authors

Irina V. Nesterova

Kuban State Medical University; P. Lumumba Peoples’ Friendship University

Author for correspondence.
Email: inesterova1@yandex.ru
ORCID iD: 0000-0001-6071-4409
SPIN-code: 4714-2488
Scopus Author ID: 56553330300
ResearcherId: A-8785-2016

Doctor of Medical Sciences, Professor, Chief Researcher, Department of Clinical and Experimental Immunology and Molecular Biology, Central Scientific Research Laboratory, Professor of the Department of Clinical Immunology, Allergology and Adaptology Faculty of Continuing Medical Education of the Medical Institute

Russian Federation, 350063, Krasnodar, st. Mitrofan Sedin, 4; 117198, Moscow, st. Miklukho-Maklaya, 6

Galina A. Chudilova

Kuban State Medical University

Email: chudilova2015@yandex.ru
ORCID iD: 0000-0001-8005-9325
SPIN-code: 2092-6412
Scopus Author ID: 6507554434
ResearcherId: AAB-2922-2020

Doctor of Biological Sciences, Associate Professor, head of the department of clinical and experimental immunology and molecular biology of the Central Scientific Research Laboratory, Professor of the Department of Clinical Immunology, Allergology and Laboratory Diagnostics of the Faculty of Professional Development and Professional Retraining of Specialists

Russian Federation, 4, st. Mitrofan Sedin, Krasnodar, 350063

Margarita G. Atazhakhova

Kuban State Medical University

Email: doctor_atazhachova@mail.ru
ORCID iD: 0000-0002-5516-4964

Postgraduate Student, Department of Clinical Immunology, Allergology and Laboratory Diagnostics of FAT and PRS

Russian Federation, 4, st. Mitrofan Sedin, Krasnodar, 350063

Valeriya A. Matushkina

Kuban State Medical University

Email: lm.mva@yandex.ru
ORCID iD: 0000-0001-6407-6598

Assistant of the Department of Infectious Diseases and Epidemiology of FAT and PRS

Russian Federation, 4, st. Mitrofan Sedin, Krasnodar, 350063

Svetlana V. Kovaleva

Kuban State Medical University

Email: 3483335@mail.ru
ORCID iD: 0000-0002-9604-5806
SPIN-code: 8289-5342
Scopus Author ID: 55535685400
ResearcherId: AAB-3408-2020

Doctor of Medical Sciences (MD), Associate Professor, senior researcher of the department of clinical and experimental immunology and molecular biology of the Central Scientific Research Laboratory, Associate Professor of the Department of Clinical Immunology, Allergology and Laboratory Diagnostics of FAT and PRS

Russian Federation, 4, st. Mitrofan Sedin, Krasnodar, 350063

Valeriya N. Chapurina

Kuban State Medical University

Email: Pavlenkoevi2016@yandex.ru
ORCID iD: 0000-0002-1912-2038

assistant of the Department of Clinical Immunology, Allergology and Laboratory Diagnostics of FAT and PRS

Russian Federation, 4, st. Mitrofan Sedin, Krasnodar, 350063

References

  1. Белопасов В.В., Журавлева Е.Н., Нугманова Н.П., Абдрашитова А.Т. Постковидные неврологические синдромы // Клиническая практика, 2021. Т. 12, № 2. С. 69-82. [Belopasov V.V., Zhuravleva E.N., Nugmanova N.P., Abdzashitova A.T. Post-COVID-19 Neurological Syndromes. Klinicheskaya praktika = Journal of Clinical Practic, 2021, Vol. 12, no. 2, pp. 69-82. (In Russ.)]
  2. Канорский С.Г. Постковидный синдром: распространенность и патогенез органных поражений, направления коррекции. Систематический обзор // Кубанский научный медицинский вестник, 2021. T. 28, № 6. C. 90-116. [Kanorsky S.G. Postcovid syndrome: prevalence and pathogenesis of organ lesions, directions of correction. Systematic review. Kubanskiy nauchnyy meditsinskiy vestnik = Kuban Scientific Medical Bulletin, 2021, Vol. 28, no. 6, pp. 90-116. (In Russ.)]
  3. Ковальчук В.В., Дроздова М.С., Чепель Ю.А., Нестерин К.В. Постковидный синдром. Мифы и реалии // Эффективная фармакотерапия, 2022. T. 18, № 23. C. 20-26. [Kovalchuk V.V., Drozdova M.S., Chepel Yu.A., Nesterin K.V. Postcovid syndrome. Myths and realities. Effektivnaya farmakoterapiya = Effective Pharmacotherapy, 2022, Vol. 18, no. 23, pp. 20-26. (In Russ.)]
  4. Методические рекомендации «Особенности течения Long-COVID инфекции. Терапевтические и реабилитационные мероприятия» // Терапия, 2022. T. 1 (Приложение). C. 1-147. [Methodological recommendations “Features of Long-COVID infection clinical course. Therapeutic and rehabilitation measures”. Terapiya = Therapy, 2022, Vol. 1 (Suppl.), pp. 1-147. (In Russ.)]
  5. Нестерова И.В., Городин В.Н., Чудилова Г.А., Чапурина В.Н., Матушкина В.А., Габдрахманова Р.Ю., Ломтатидзе Л.В., Ковалева С.В., Малиновская В.В., Семененко Т.А. Эффекты влияния рекомбинантного интерферона α-2b на фенотип субпопуляций нейтрофильных гранулоцитов пациентов с COVID-19 // Инфекционные болезни, 2022. T. 20, № 1. C. 43-51. [Nesterova I.V., Gorodin V.N., Chudilova G.A., Chapurina V.N., Matushkina V.A., Gabdrakhmanova R.Yu., Lomtatidze L.V., Kovaleva S.V., Malinovskaya V.V., Semenenko T.A. Effects of recombinant interferon α-2b on the phenotype of neutrophil granulocyte subpopulations of patients with COVID-19. Infektsionnye bolezni = Infectious Diseases, 2022, Vol. 20, no. 1, pp. 43-51. (In Russ.)]
  6. Нестерова И.В., Ковалева С.В., Чудилова Г.А., Халтурина Е.О., Малиновская В.В. Врожденные и приобретенные интерферонопатии, ассоциированные с нетипично протекающими вирусными инфекциями и с COVID-19 // Иммунотерапия в практике ЛОР-врача и терапевта / Под ред. А.С. Симбирцев, Г.В. Лавренова. СПб.: Диалог, 2022. С. 234-269. [Nesterova I.V., Kovaleva S.V., Chudilova G.A., Khalturina E.O., Malinovskaya V.V. Congenital and acquired interferonopathies associated with atypical viral infections and COVID-19. Immunotherapy in the practice of ENT doctor and therapist / Ed. Simbirtsev A.S., Lavrenova G.V]. St. Petersburg: Dialog, 2022, pp. 234-269.
  7. Нестерова И.В., Халтурина Е.О., Малиновская В.В. Клинико-иммунологическая эффективность интеграционной программы реабилитации иммунной системы у пациентов с атипичной хронической активной герпесвирусной коинфекцией до и во время COVID-19, а также в постковидном периоде // Эффективная фармакотерапия, 2022. Т. 18, № 37. С. 30-41. [Nesterova I.V., Khalturina E.O., Malinovskaya V.V. Clinical and immunological effectiveness of the integration program for the rehabilitation of the immune system in patients with atypical chronic active herpesvirus coinfection before and during COVID-19, as well as in the postcovid period. Effektivnaya farmakoterapiya = Effective Pharmacotherapy, 2022, Vol. 18, no. 37, pp. 30-41. (In Russ.)]
  8. Хасанова Д.Р., Житкова Ю.В., Васкаева Г.Р. Постковидный синдром: обзор знаний о патогенезе, нейропсихиатрических проявлениях и перспективах лечения // Неврология, нейропсихиатрия, психосоматика, 2021. T. 13, № 3. C. 93-98. [Khasanova D.R., Zhitkova Yu.In, Maskaeva G.R. Postcovid syndrome: a review of knowledge about pathogenesis, neuropsychiatric manifestations and treatment prospects. Nevrologiya, neyropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics, 2021, Vol. 13, no. 3, pp. 93-98. (In Russ.)]
  9. Chua R.L., Lukassen S., Trump S., Hennig B.P., Wendisch D., Pott F., Debnath O., Thürmann L., Kurth F., Völke M.T., Kazmierski J., Timmermann B., Twardziok S., Schneider S., Machleidt F., Müller-Redetzky H., Maier M., Krannich A., Schmidt S., Balzer F., Liebig J., Loske J., Suttorp N., Eils J., Ishaque N., Liebert U.G., von Kalle C., Hocke A., Witzenrath M., Goffinet C., Drosten C., Laudi S., Lehmann I., Conrad C., Sander L.-E., Eils R. COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. Nat. Biotechnol., 2020, Vol. 38, pp. 970-979.
  10. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline. Available at: www.nice.org.uk/guidance/ng188.
  11. Nesterova I.V., Khalturina E.O., Malinovskaya V.V., Nguen T.L. Recombinant IFNα2b in complex with immunotropic drugs restored antiviral functions of subset iFNα/βR1+IFNγR+TLR4+NG neutrophilic granulocyte and demonstrated good clinical efficacy in patients with active chronic herpes-viral infections and chronic fatigue syndrome. Allergy & asthma, COVID-19 & COPD, immunophysiology & immunorehabilitology: innovative technologies. Ed. R. Sepiashvili. Bologna: Filodiritto Publishe, 2021, pp. 70-78.
  12. Reusch N., de Dominico E., Bonaguro L., Schulte-Schrepping J., Babler K., Schultze J.L., Aschenbrenner A.C. Neutrophils in COVID-19. Front. Immunol., 2021, Vol. 12, 652470. doi: 10.3389/fimmu.2021.652470.
  13. Simonnet A., Engelmann I., Moreau A.S., Garciaa B., Sixa S., Kalioubie A.E., Robriquet L, Hober D., Jourdain M. High incidence of Epstein–Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect. Dis. Now, 2021, Vol. 51, no. 3, pp. 296-299.
  14. Whiteside D.M., Oleynick V., Holker E., Waldron E.J., Porter J., Kasprzak M. Neurocognitive deficits in severe COVID-19 infection: Case series and proposed model. Clin. Neuropsychol., 2021, Vol. 35, no. 4, pp. 799-818.
  15. Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., Ji R., Wang H., Wang Y., Zhou Y. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis., 2020, Vol. 94, pp. 91-95.

Copyright (c) 2023 Nesterova I.V., Chudilova G.A., Atazhakhova M.G., Matushkina V.A., Kovaleva S.V., Chapurina V.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies